🇺🇸 FDA
Patent

US 8569225

Targeting complement factor H for treatment of diseases

granted A61KA61K38/00A61P

Quick answer

US patent 8569225 (Targeting complement factor H for treatment of diseases) held by The Regents of the University of Colorado, a Body Corporate expires Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of Colorado, a Body Corporate
Grant date
Tue Oct 29 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 24 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/00, A61P, A61P1/04, A61P11/06